Literature DB >> 27417291

Age-related risk factors for bacterial aetiology in community-acquired pneumonia.

José M Sahuquillo-Arce1, Rosario Menéndez2,3, Raúl Méndez4,5, Isabel Amara-Elori4,5, Rafael Zalacain6, Alberto Capelastegui7, Javier Aspa8, Luis Borderías9, Juan J Martín-Villasclaras10, Salvador Bello11, Inmaculada Alfageme12, Felipe Rodriguez de Castro13, Jordi Rello14,15, Luis Molinos16, Juan Ruiz-Manzano17, Antoni Torres5,18.   

Abstract

BACKGROUND AND
OBJECTIVE: The objective of this study was to evaluate the effect of age and comorbidities, smoking and alcohol use on microorganisms in patients with community-acquired pneumonia (CAP).
METHODS: A prospective multicentre study was performed with 4304 patients. We compared microbiological results, bacterial aetiology, smoking, alcohol abuse and comorbidities in three age groups: young adults (<45 years), adults (45-64 years) and seniors (>65 years).
RESULTS: Bacterial aetiology was identified in 1522 (35.4%) patients. In seniors, liver disease was independently associated with Gram-negative bacteria (Haemophilus influenzae and Enterobacteriaceae), COPD with Pseudomonas aeruginosa (OR = 2.69 (1.46-4.97)) and Staphylococcus aureus (OR = 2.8 (1.24-6.3)) and neurological diseases with S. aureus. In adults, diabetes mellitus (DM) was a risk factor for Streptococcus pneumoniae and S. aureus, and COPD for H. influenzae (OR = 3.39 (1.06-10.83)). In young adults, DM was associated with S. aureus. Smoking was a risk factor for Legionella pneumophila regardless of age. Alcohol intake was associated with mixed aetiology and Coxiella burnetii in seniors, and with S. pneumoniae in young adults.
CONCLUSION: It should be considered that the bacterial aetiology may differ according to the patient's age, comorbidities, smoking and alcohol abuse. More extensive microbiological testing is warranted in those with risk factors for infrequent microorganisms.
© 2016 Asian Pacific Society of Respirology.

Entities:  

Keywords:  age; community-acquired pneumonia; comorbidities; risk factors; smoking and alcohol use

Mesh:

Year:  2016        PMID: 27417291     DOI: 10.1111/resp.12851

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  11 in total

Review 1.  Year in review 2016: Respiratory infections, acute respiratory distress syndrome, pleural diseases, lung cancer and interventional pulmonology.

Authors:  Marcos I Restrepo; James D Chalmers; Yuanlin Song; Christopher Mallow; Justin Hewlett; Fabien Maldonado; Lonny Yarmus
Journal:  Respirology       Date:  2017-02-28       Impact factor: 6.424

2.  [Clinical characteristics of influenza pneumonia in the elderly and relationship between D-dimer and disease severity].

Authors:  J Li; Y Xu; Y Y Wang; Z C Gao
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-02-18

Review 3.  Burden of Community-Acquired Pneumonia and Unmet Clinical Needs.

Authors:  João Ferreira-Coimbra; Cristina Sarda; Jordi Rello
Journal:  Adv Ther       Date:  2020-02-18       Impact factor: 3.845

4.  Proposing a "Brain Health Checkup (BHC)" as a Global Potential "Standard of Care" to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of "Dopamine Homeostasis".

Authors:  Eric R Braverman; Catherine A Dennen; Mark S Gold; Abdalla Bowirrat; Ashim Gupta; David Baron; A Kenison Roy; David E Smith; Jean Lud Cadet; Kenneth Blum
Journal:  Int J Environ Res Public Health       Date:  2022-04-30       Impact factor: 4.614

5.  The Role of Pneumococcal Pneumonia among Community-Acquired Pneumonia in Adult Turkish Population: TurkCAP Study.

Authors:  Esin Şenol; Aykut Çilli; Hakan Günen; Alper Şener; Rıdvan Dumlu; Ayşe Ödemiş; Ayşe Füsun Topçu; Yeşim Yıldız; Rahmet Güner; Ayhan Özhasenekler; Birsen Mutlu; Nurdan Köktürk; Nurgül Sevimli; Nurcan Baykam; Derya Yapar; Selami Ekin; Mehmet Polatlı; Şebnem Eren Gök; Oğuz Kılınç; Abdullah Sayıner; Ömer Karaşahin; Çağlar Çuhadaroğlu; Ayşe Sesin Kocagöz; Turhan Togan; Hüseyin Arpağ; Hakan Katı; İftihar Köksal; Firdevs Aksoy; Canan Hasanoğlu
Journal:  Turk Thorac J       Date:  2021-07

Review 6.  Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients.

Authors:  Jesús López-Alcalde; Ricardo Rodriguez-Barrientos; Jesús Redondo-Sánchez; Javier Muñoz-Gutiérrez; José María Molero García; Carmen Rodríguez-Fernández; Julio Heras-Mosteiro; Jaime Marin-Cañada; Jose Casanova-Colominas; Amaya Azcoaga-Lorenzo; Virginia Hernandez Santiago; Manuel Gómez-García
Journal:  Cochrane Database Syst Rev       Date:  2018-09-06

7.  Inappropriate Use of Antimicrobials for Lower Respiratory Tract Infections in Elderly Patients: Patient- and Community-Related Implications and Possible Interventions.

Authors:  Inger van Heijl; Valentijn A Schweitzer; Lufang Zhang; Paul D van der Linden; Cornelis H van Werkhoven; Douwe F Postma
Journal:  Drugs Aging       Date:  2018-05       Impact factor: 3.923

8.  Differences between diabetic and non-diabetic patients with community-acquired pneumonia in primary care in Spain.

Authors:  Loreto Arias Fernández; Jacobo Pardo Seco; Miriam Cebey-López; Ruth Gil Prieto; Irene Rivero-Calle; Federico Martinon-Torres; Ángel Gil de Miguel; F Martinón-Torres; D Vargas; E Mascarós; E Redondo; J L Díaz-Maroto; M Linares-Rufo; A Gil; J Molina; D Ocaña; I Rivero-Calle
Journal:  BMC Infect Dis       Date:  2019-11-15       Impact factor: 3.090

9.  Incidence rate of community-acquired pneumonia in adults: a population-based prospective active surveillance study in three cities in South America.

Authors:  Gustavo Daniel Lopardo; Diego Fridman; Enrique Raimondo; Henry Albornoz; Ana Lopardo; Homero Bagnulo; Daniel Goleniuk; Manuelita Sanabria; Daniel Stamboulian
Journal:  BMJ Open       Date:  2018-04-10       Impact factor: 2.692

Review 10.  [Three keys to the appropriate choice of oral antibiotic treatment in the respiratory tract infections].

Authors:  R Menéndez; R Cantón; A García-Caballero; J Barberán
Journal:  Rev Esp Quimioter       Date:  2019-12-04       Impact factor: 1.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.